Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Cerebral Blood Flow Regulation: Sex, Mechanism, and Stress Differences (Phase 2)
NCT06253702Phase 4Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of indomethacin in cerebrovascular disease (4 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Cerebral Blow Flow: Hormone Suppression Hypoxia Condition at 7 days, Cerebral Blow Flow: Hormone Suppression Hypercapnia Condition at 7 days and 2 more. Started Jul 2024; status: completed.
02
Drugs
indomethacin
03
Conditions
cerebrovascular disease
Beyond the preview
Go deeper on NCT06253702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253702.